Cargando…
Clostridium difficile--a moving target
Clostridium difficile has been recognized as a pathogen in humans for over 40 years, but in the past decade the incidence has increased and, more importantly, the clinical presentation and consequences have become more serious, with increased morbidity and mortality. The emergence of a new, more pat...
Autores principales: | Tillotson, Glenn S., Tillotson, Joni |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096886/ https://www.ncbi.nlm.nih.gov/pubmed/21654927 http://dx.doi.org/10.3410/M3-6 |
Ejemplares similares
-
Clostridium difficile Infections among Hospitalized Children, United States, 1997–2006
por: Zilberberg, Marya D., et al.
Publicado: (2010) -
Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023) -
Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023) -
Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022) -
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
por: Vickers, Richard, et al.
Publicado: (2015)